Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors

Simple item page
dc.contributor.authorFreimane, Lauma
dc.contributor.authorBarkāne, Linda
dc.contributor.authorKivrane, Agnija
dc.contributor.authorSadovska, Darja
dc.contributor.authorUlanova, Viktorija
dc.contributor.authorRanka, Renāte
dc.contributor.institutionFaculty of Pharmacy
dc.date.accessioned2023-12-06T11:55:01Z
dc.date.available2023-12-06T11:55:01Z
dc.date.issued2023-04
dc.descriptionPublisher Copyright: © 2023 by the authors.
dc.description.abstractFollowing the introduction of all-oral treatment regimens for patients with drug-resistant tuberculosis (TB), second-line injectable drug applications have been reduced in the last few years. However, they are still important for anti-TB therapy. This study aims to analyze the occurrence of amikacin- and capreomycin-related adverse drug reactions (ADR) in patients with multidrug-resistant tuberculosis (MDR-TB) and evaluate the role of multiple patient-, disease-, and therapy-related factors on the frequency of the observed adverse events. In addition, the possible role of genetic risk factors was studied by full-length mitochondrial DNA sequencing. Toward this aim, we retrospectively evaluated 47 patients with MDR-TB who received amikacin and/or capreomycin. In total, 16 (34.0%) patients developed ototoxicity and 13 (27.7%) developed nephrotoxicity, including 3 (6.4%) patients who experienced both adverse events. Ototoxicity development was more common in patients who received amikacin. No other factors showed a significant impact. Nephrotoxicity was likely associated with previous renal health impairment. Full mitochondrial genome sequencing did not reveal any specific ADR-associated variants, and results showed no differences in adverse event occurrence for any specific variants, mutation count, or mitochondrial haplogroup. The absence of the previously reported ototoxicity-related mtDNA variants in our patients with ototoxicity and nephrotoxicity highlighted the complex nature of the ADR occurrence.en
dc.description.statusPeer reviewed
dc.format.extent665821
dc.identifier.citationFreimane, L, Barkāne, L, Kivrane, A, Sadovska, D, Ulanova, V & Ranka, R 2023, 'Assessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factors', Journal of Personalized Medicine, vol. 13, no. 4, 599. https://doi.org/10.3390/jpm13040599
dc.identifier.doi10.3390/jpm13040599
dc.identifier.issn2075-4426
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/15030
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85154541857&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofJournal of Personalized Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectamikacin
dc.subjectcapreomycin
dc.subjectMDR-TB
dc.subjectnephrotoxicity
dc.subjectototoxicity
dc.subject3.1 Basic medicine
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectMedicine (miscellaneous)
dc.subjectSDG 3 - Good Health and Well-being
dc.titleAssessment of Amikacin- and Capreomycin-Related Adverse Drug Reactions in Patients with Multidrug-Resistant Tuberculosis and Exploring the Role of Genetic Factorsen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jpm-13-00599.pdf
Size:
650.22 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure